Treatment of Optic Neuritis in Antiphospholipid Syndrome

Immediate Treatment Protocol

The European League Against Rheumatism recommends initiating high-dose intravenous methylprednisolone 1000 mg/day for 3-5 days plus anticoagulation therapy for optic neuritis occurring in the context of antiphospholipid syndrome, addressing both inflammatory and thrombotic mechanisms 1, 2
The American College of Rheumatology suggests starting IV methylprednisolone 1000 mg/day for 3-5 days immediately upon diagnosis, as delays beyond 2 weeks are associated with significantly worse visual outcomes 1, 2, 3
The European League Against Rheumatism recommends initiating therapeutic anticoagulation concurrently with warfarin or other appropriate anticoagulant, targeting therapeutic INR levels, as antiphospholipid syndrome creates a prothrombotic state that contributes to optic nerve ischemia 1

The American Academy of Neurology recommends determining whether this is true inflammatory optic neuritis versus ischemic optic neuropathy, as the latter is more common with antiphospholipid antibodies and is typically unilateral 1, 4
The American Academy of Ophthalmology suggests performing complete ophthalmological evaluation including funduscopy, fluorescein angiography, visual evoked potentials, and MRI of brain and orbits with contrast 1, 2

The European League Against Rheumatism recommends following initial IV methylprednisolone with oral prednisone taper (typically 1 mg/kg/day for 11 days with 4-day taper) to prevent early relapse 3
The American College of Rheumatology suggests implementing maintenance immunosuppression to prevent the 50-60% relapse rate seen during steroid dose reduction 1, 5, 3

The American Academy of Neurology recommends considering plasma exchange (PLEX) for severe cases with progressive vision loss not responding to IV steroids within 3-5 days 2, 4, 3
The European League Against Rheumatism suggests using rituximab for refractory cases, particularly when standard immunosuppression fails 2, 4

The American Academy of Ophthalmology recommends ophthalmological evaluations every 4-6 weeks including visual acuity, visual fields, funduscopy, and contrast sensitivity 3
The American Academy of Neurology suggests using visual evoked potentials to objectively assess optic nerve recovery and detect subclinical bilateral involvement 1, 2, 3

The European League Against Rheumatism notes that visual outcomes in antiphospholipid-associated optic neuritis are generally poorer than typical optic neuritis, with treatment failures being common even with appropriate therapy 1, 4
The American College of Rheumatology suggests that patients may have concurrent systemic lupus erythematosus, which would warrant even more aggressive immunosuppression with cyclophosphamide added to the regimen 1, 5, 4